Top Markets
#1 Black Phoenix Black Phoenix +355.52%
#2 Glidr Glidr +84.34%
#3 Gold Park Gold Park +55.17%
#4 Akedo Akedo +48.78%
#5 Acurast Acurast +29.95%
#6 BasedHype BasedHype +23.54%
#7 Cryptopia Cryptopia +21.54%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +21.11%
#9 Avantis Avantis +20.16%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +15.50%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Vincerx Pharma, Inc. Vincerx Pharma, Inc.

Vincerx Pharma, Inc.

VINC
Rank in Stocks #40876
Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical... Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.
Share Price
$0.0127
Last synced: 2026-08-12
Market Cap
$66.48K
Change (1 day)
-2.31%
Change (1 year)
-67.44%
Country
US
Trade Vincerx Pharma, Inc. (VINC)

Category

Healthcare
Revenue for Vincerx Pharma, Inc. (VINC)
Revenue in Aug 2026 TTM: 0
According to Vincerx Pharma, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Vincerx Pharma, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE